Consider Cardiovascular Benefits When Recommending a GLP-1 Agonist
Trulicity (dulaglutide) will be the third GLP-1 agonist to show CV benefits in some patients with type 2 diabetes.
It joins Ozempic (semaglutide) and Victoza (liraglutide). All three lower CV risk in type 2 patients with CV disease or at high CV risk.
Each of these meds also seems to slow progression to albuminuria...but isn't shown to delay dialysis.